KKR & Co. closed Tuesday at $110.97, up nearly 7% on the day, and the stock has now run far enough that the debate shifts from whether the rally is real to whether the analyst community has caught up with it.
The short side tells a straightforward story: bears are backing away. Short interest slipped to 1.6% of free float, down nearly 14% in a single session on August 11 after a brief uptick on August 10. The month-on-month trend is cleaner still — shorts have cut exposure by roughly 8% over the past 30 days, unwinding a cluster that had been building since mid-July when shares-short hovered around 16.6 million. Borrow conditions remain almost entirely frictionless: availability is effectively uncapped, with over 527 million shares available versus roughly 14 million on loan. Cost to borrow has crept up 40% over the week to 0.44%, but that number in absolute terms is still trivially cheap — there is no mechanical squeeze pressure here. The ORTEX short score of 32.8 sits near the bottom half of the universe, consistent with a stock where short interest is a non-event rather than a tension point.
Options tell a more nuanced story. The put/call ratio eased slightly to 1.92 — still well above its 52-week low of 0.98 — and has been running structurally elevated for months. The z-score of 0.95 puts the current reading within one standard deviation of the recent mean, so the elevated PCR reflects an entrenched pattern of hedging rather than a fresh spike in fear. This is a stock where put buyers are perennial, probably because the name has enough institutional concentration that large holders routinely collar positions. The intensity of defensiveness flagged in last week's trader note has softened, not escalated.
The Street has been unanimous in one direction: raise targets. Following the July 30 Q2 print, every firm that acted lifted its number. Barclays moved to $135, RBC to $134, Morgan Stanley trimmed from $153 to $147 but kept Overweight intact, and Argus Research pushed to $125 just last week. The consensus mean now sits at $126.53 — roughly a 14% premium to Tuesday's close. The one dissenting voice remains TD Cowen, holding at $111 with a Hold rating, which at current prices effectively signals the stock is now fairly valued in that framework. Factor scores lean constructive: analyst recommendation differential ranks in the 91st percentile, forward EPS momentum is positive over both 30- and 90-day windows, and the days-to-cover rank is in the 73rd percentile. The bear case centres on macro-driven headwinds to traditional PE and credit, plus a reduced $7 ANI/share guide for 2026. Bulls counter with fundraising momentum, the employee-ownership model in portfolio companies, and a diversified fee stream that has repeatedly absorbed volatility better than peers.
Peer performance on the day reinforced the sector-wide bid: BX gained 3.9%, ARES added 4.0%, and STEP led the group with 7.3%. CG was the laggard on the week, slipping 4.5%. KKR's 2.6% weekly gain sits in the middle of the pack — the stock isn't dramatically outperforming its alternative-asset-manager cohort, which makes the single-session jump on Tuesday look more like catch-up after a brief consolidation than a standalone catalyst.
The next earnings event is October 30, and given that the last two prints produced 2.2% and 0.9% moves respectively — both quickly followed by five-day gains of around 4% — the pattern heading into that date is one where the fundamental narrative has consistently held up post-release. What to watch between now and then is whether the gap between TD Cowen's $111 target and the broader consensus at $126–$135 begins to narrow through further upgrades, or whether the stock's proximity to the lower end of the target cluster is enough to dampen incremental buying pressure.
See the live data behind this article on ORTEX.
Open KKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
